BeOne Medicines AG DRC (ONC)
BeOne Medicines AG DRC (NASDAQ: ONC) is a depositary receipt representing common stock of BeOne Medicines AG, a Switzerland-based oncology company headquartered in Basel. The company develops and commercializes therapies for cancer patients across the United States, China, Europe, and other international markets. Its commercial portfolio includes BRUKINSA, a BTK inhibitor for certain blood cancers; TEVIMBRA, an anti-PD-1 immunotherapy used in multiple solid and blood tumors; SYLVANT; BAITUOWEI; and PARTRUVIX. BeOne also maintains a broad pipeline spanning clinical and preclinical programs, including candidates such as Sonrotoclax BGB-11417, BGB-16673, BG-60366, BG-89894 (SYH2039), and several antibody, inhibitor, and ADC programs. The company has collaboration agreements with Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. Formerly known as BeiGene, Ltd., it adopted the BeOne Medicines AG name in May 2025.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ONC
|
$369.09
|
-2.3% Downside
|
Fair
|
$436.46
|
15.6% Upside
|
Fair
|
Great
|
0.0%
|
November 10, 2026
|
65.5x
|
8.3x
|
7.0x
|
42.937 B
|
39.889 B
|
4.6%
|
71.2%
|
6.1
|
202.9%
|
